Lenvatinib (Lenvima)
. Draft fact sheet, awaiting Henry's approval. Items marked [check] must be verified before publishing.
← All drugs · Search the portal
Facts
| Topic | Fact | Source (access date) |
|---|---|---|
| First approval | US 13 Feb 2015 (Eisai); EU 28 May 2015; China Sep 2018 (liver cancer) | Drugs@FDA via openFDA, https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA206947 (accessed 4 Nov 2026); EMA medicines report, https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx (accessed 4 Nov 2026); Eisai https://www.eisai.com/news/2018/news201877.html (4 Nov 2026) |
| Mechanism | Tyrosine kinase inhibitor acting on VEGF, FGF and RET receptors; capsules by mouth | EMA EPAR https://www.ema.europa.eu/en/medicines/human/EPAR/lenvima (accessed 4 Nov 2026) |
| Use in osteosarcoma | Relapse, trials only; UK compassionate access | UK bone sarcoma guidelines 2024, https://pmc.ncbi.nlm.nih.gov/articles/PMC11723950/ (accessed 3 Nov 2026) |
| Combined with | Ifosfamide and etoposide (ITCC-050, OLIE); everolimus (NCT07619950) | entries.json (portal export), sources opened 31 Oct to 3 Nov 2026 |
| Results | ITCC-050: 4-month PFS 51% (35 patients). OLIE (NCT04154189, 81 patients aged 2 to 25): median PFS 6.5 v 5.5 months, HR 0.54, one-sided P=.04, not significant; 4-month PFS 76.3% v 66.0%; median OS 11.9 months with lenvatinib v 17.4 months without (HR 1.28); grade 3+ treatment-related events 89.7% v 79.5% | Gaspar et al., JAMA Oncol 2024, doi:10.1001/jamaoncol.2024.4381 (PMID 39418029) (accessed 4 Nov 2026); entries.json |
| Side effects | More than 3 in 10: high blood pressure, diarrhoea, lower appetite and weight, tiredness, nausea, protein in urine, mouth inflammation, vomiting, hoarse voice, headache, hand-foot skin reaction | EMA EPAR Lenvima (accessed 4 Nov 2026) |
| Owner | Discovered by Eisai; global co-development and co-commercialisation with Merck (MSD) agreed March 2018; EU holder Eisai GmbH | Eisai, https://www.eisai.com/news/2018/news201818.html (accessed 4 Nov 2026); EMA EPAR (accessed 4 Nov 2026) |
| Regulatory | US, EU, UK, China: thyroid, liver, kidney, endometrial cancers. Not osteosarcoma | entries.json (portal export), sources opened 31 Oct to 3 Nov 2026 |
Hypotheses and open points (not established fact)
- None recorded.